Infection and Immunity, October 2000, p. 5756-5763, Vol. 68, No. 10
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


Novartis Pharma Limited, CH-4002 Basel,1 and Theodor-Kocher Institute, University of Bern, CH-3012 Bern,2 Switzerland, and Fund for Molecular Hematology and Immunology, Moscow, Russia3
Received 31 January 2000/Returned for modification 24 April 2000/Accepted 3 July 2000
| |
ABSTRACT |
|---|
|
|
|---|
Interleukin-8 (IL-8) is elevated in the cerebrospinal fluid (CSF) of patients with meningitis and is proposed to participate in subarachnoid-space pleocytosis. However, intracisternal injection of IL-8 into rabbits failed to induce indices typical of meningitis (leukocyte, tumor necrosis factor, or protein accumulation in the CSF or histopathological changes), indicating that merely increasing the CSF level of this chemokine is insufficient to induce inflammation in this anatomical site. IL-8 treatment did not affect inflammatory responses to subsequently intracisternally administered lipopolysaccharide (LPS). IL-8 was chemotactic for rabbit neutrophils in vitro, and subcutaneous injection of IL-8 (diluted in buffer or CSF) proved the in vivo activity of this peptide and suggested the absence of an IL-8 inhibitor in normal rabbit CSF. LPS-dependent pleocytosis was only slightly diminished by intracisternally administered murine anti-rabbit IL-8 monoclonal antibody (MAb) WS-4 but was dramatically reduced by intravenously administered MAb. Therefore, elevated CSF IL-8 levels may contribute to, but cannot solely account for, neutrophil influx into the subarachnoid space during meningitis. However, inhibition of IL-8 activity of the bloodstream side of the blood-brain barrier effectively reduces pleocytosis, indicating a central role of IL-8 in neutrophil influx into CSF during bacterial meningitis. Thus, inhibition of IL-8 is a possible therapeutic target for adjunct treatment of meningitis.
| |
INTRODUCTION |
|---|
|
|
|---|
In bacterial meningitis, a marked
inflammatory reaction takes place in the subarachnoid space that is
initiated by bacterial components (peptidoglycan, lipopolysaccharide
[LPS]) that induce proinflammatory cytokines (e.g., interleukin-1
[IL-1], tumor necrosis factor alpha [TNF-
]). This inflammatory
pathology has been linked to the development of neurological sequelae
that follow bacteriological cure (6, 17, 55). A
characteristic feature of this inflammatory response is the presence of
neutrophils in the cerebrospinal fluid (CSF). IL-8, a member of the
C-X-C chemokine family of peptide cytokines, is a potent mediator of
inflammation. In neutrophils, the primary target cells of IL-8 and
several other chemokines, IL-8 induces chemotaxis, enzyme release from
storage granules, production of oxygen radicals, and upregulation of
adhesion molecules (2, 63). Notably, IL-8 is regarded to
play an important role in the pathology of inflammatory diseases, since
(i) large quantities of this cytokine can be found in situ at
inflammatory sites; (ii) many tissue cells produce IL-8 when activated
by IL-1, TNF, or LPS (2, 63); and (iii) finally, anti-IL-8
antibody reduces neutrophil infiltration at the site of inflammation
(35).
However, the role of chemokines in bacterial meningitis is not well
understood. Experimentally, IL-8 has been detected in the CSF of
rabbits with Streptococcus pneumoniae meningitis, and CSF
IL-8 levels begin to rise just before commencement of pleocytosis (38); furthermore, the authors of that study report that an anti-rabbit IL-8 antibody attenuates the inflammatory response (C. Østergaard, T. L. Benfield, N. Frimodt-Møller, F. Espersen, N. Mukaida, K. Matsushima, C. G. Larsen, and J. D. Lundgren,
Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 2043, 1999). Macrophage inflammatory protein-1
(MIP-1
) and MIP-2 (the murine homolog of GRO, but possessing activity functionally similar to
IL-8) are produced intrathecally in mice with Listeria
monocytogenes infection, and antibodies to these chemokines can
neutralize the chemotactic activity of CSF ex vivo (45).
Haemophilus influenzae meningitis in infant rats was
associated with elevated MIP-1
, MIP-2, methyl-accepting chemotaxis
protein 1 (MCP-1), and regulated upon activation, normal T cell
expressed and secreted chemokine (RANTES) mRNA in the subarachnoid
space, and antibodies to MIP-1
and MIP-2 reduced neutrophil influx,
while antibodies to MCP-1 reduced macrophage influx (15).
Many clinical studies have detected IL-8 in the CSF of meningitis
patients (7, 19, 26, 29, 39, 46, 49, 51, 57, 58, 62),
suggesting that this chemokine may play a role in the accumulation of
neutrophils within the subarachnoid space. Clinically, there appears to
be a marked difference in the duration of elevated chemokine levels
between tubercular and acute bacterial meningitis, with the former
displaying protracted elevated chemokine levels compared to the latter
(32). Some (39, 51) but not all (7, 19, 26,
29, 49) of these clinical studies were able to correlate the CSF
IL-8 concentration to neutrophil levels during bacterial meningitis,
but this conclusion needs to viewed cautiously since many of these
clinical samples were from single time points at indeterminate times
after the induction of pleocytosis. However, there is some evidence
that CSF samples obtained within 12 h of onset of clinical
symptoms have higher CSF IL-8 levels than in those obtained later in
the clinical course (19). Furthermore, a recent study
demonstrated a correlation between CSF IL-8 levels and neutrophil
levels of samples obtained within 12 h of the onset of aseptic
meningitis (62). In those clinical studies considering cytokine determinations from sequential samples (26), CSF
IL-8 concentrations decreased with the commencement of disease
resolution. Many chemotactic peptides can be detected in the CSF of
meningitis patients. C-X-C (IL-8, GRO
) and C-C (MCP-1, MIP-1
, and
MIP-1
) chemokines were detected in >80% of bacterial meningitis
patient CSF samples; RANTES was found in only 25% of the samples
(49). Furthermore, the levels of C-X-C and C-C chemokines
(but not RANTES) were correlated to each other and to the leukocyte
chemotactic activity of CSF, but not to neutrophil levels, and antibody
to IL-8 was shown to dramatically (but incompletely) inhibit the neutrophil chemotactic activity possessed by CSF from meningitis patients (49). Although some studies (19, 57),
but not all of them (65), have reported increased serum IL-8
levels in such patients, it has been proposed that IL-8 could be
produced locally in the subarachnoid space during meningitis and
participates in the inflammatory process (58). The possible
sources of chemokines (microglia, astrocytes, and endothelia) and their
roles in meningitis have been reviewed (28, 55). Although
associated with damaging inflammation process, elevated IL-8 in the CNS
may be beneficial since IL-8 can activate glia and induce nerve growth
factor, which promote neuron survival (27, 34).
Although much evidence implicates IL-8 in the inflammatory response to bacterial meningitis, direct confirmation is lacking. The purpose of the present study was to examine the role of IL-8 in the development of LPS-induced neutrophil influx into the CSF of rabbits.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
IL-8 and related peptides.
Based upon the human amino acid
sequences, IL-872 (hIL-8), neutrophil activating peptide-2
(NAP-2), and GRO
were chemically synthesized (8). These
chemically synthesized peptides are comparable in activity to natural
or recombinant peptides (8, 56).
Purification of rbIL-8. Rabbit IL-8 (rbIL-8) was purified from the culture medium of rabbit alveolar macrophages stimulated with LPS as described previously (56). Alveolar macrophages were collected from rabbits by bronchioalveolar lavage with pyrogen-free phosphate-buffered saline (PBS), and adherent cells were cultured for 4 days in minimal essential medium (MEM; Gibco/Life Technologies, Basel, Switzerland) containing 2.5 µg of LPS (Escherichia coli O111:B4 [Difco]; Chemie Brunschwig AG, Basel, Switzerland) per ml and 1% (vol/vol) human plasma protein (PPL; Swiss Red Cross Laboratories, Bern, Switzerland). Conditioned medium was first diluted in 20 mM KHPO4 buffer (pH 7.2) containing 20 mM NaCl and 5% (wt/vol) glycerol and then loaded onto a phosphocellulose column (P11; Whatman; Bender and Hobein, Zürich, Switzerland). Fractions were eluted with an NaCl gradient (0.02 to 2.0 M). Based upon a purification method for human IL-8 (59), fractions demonstrating the ability to release elastase from cytochalasin-treated human neutrophils were pooled. This pool was acidified (0.1% [wt/vol] trifluoroacetic acid) and loaded onto a reversed-phase high-pressure liquid chromatography C4 column (Bakerbond, 4.6 by 250 mm; Baker Research Products, Philipsburg, N.J.) and eluted with a linear gradient of 0.67% (vol/vol) acetonitrile per min. An active fraction eluting at 59 min was collected, desiccated, resuspended in 0.1% (wt/vol) trifluoroacetic acid, loaded onto a C3 column (2.1 by 100 mm; Brownlee/Applied Biosystems; Paul Bucher, Basel, Switzerland), and eluted with a linear gradient of 1% acetonitrile (vol/vol). An active fraction eluted as a single peak at 39 min and was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to yield a single band of approximately 8 kDa (silver staining; data not shown). When subjected to automated phenyl isothiocyanate degradation analysis (Applied Biosystems gas-phase sequencer model 477A; Paul Bucher), the N-terminal sequence (NH2-Ala-Val-Leu-Try-Arg-Ile-) was shown to be identical to that of rabbit IL-8 (3, 12).
In vitro chemotaxis. Rabbit blood was collected from the lateral ear vein into 10% acid citrate dextrose, and total leukocytes were prepared from the buffy coat, washed, and resuspended in PBS containing 0.2% (wt/vol) PPL. Human neutrophils were obtained from healthy volunteers and were similarly prepared. Neutrophil migration was determined using multiwell chemotaxis chambers (Neuro Probe, Cabin John, Md.), essentially as previously described (60). Rabbit IL-8 (and the human chemokines) only induced the migration of neutrophils (not shown).
Sterile meningitis model. The Ethical Committee of the Kantonales Veterinäramt of Basel Stadt approved the experimental protocols involving animals. Specific-pathogen-free chinchilla rabbits, 2.5 to 3 kg in weight, were obtained from Thomae, Biberach an der Riss, Germany. On the day before an experiment, rabbits were anesthetized with a combination of fentanyl and fluanisone (Hypnorm; Janssen Pharmaceutica AG, Baar, Switzerland) and were fitted with prostheses to facilitate placement within a stereotactic frame according to an established method (13). Prior to the injection of peptides, rabbits received 1.75 g of ethyl carbamate (urethane) per kg of body weight subcutaneously and then 10 mg of pentobarbital intravenously per kg to induce deep, long-term anesthesia. The animals were fixed in a stereotactic frame, and 3.5-in. spinal needles (25 g) were sited in the cisterna magna to allow repeated sampling of the CSF. Following the withdrawal of 0.4 ml of CSF, various amounts of peptide (diluted in 0.2 ml of pyrogen-free physiological saline [PFS]) were introduced into the subarachnoid space, and the needle was flushed with 0.1 ml of CSF. CSF (0.2 ml) was sampled at 2, 4, 6, and 8 h postinjection. The rate of removal of CSF did not exceed the rate of CSF formation (approximately 0.4 ml/h [50]). At 8 h, if no evidence of pleocytosis was observed, 25 ng of LPS (E. coli O111:B4; Sigma) in 0.2 ml of PFS or PFS alone was administered intracisternally, and CSF was sampled 2 and 4 h later. At 12 h after the start of the experiment, rabbits were sacrificed using an overdose of T61 (Hoescht Veterinär GmbH, Munich, Germany). At least two rabbits were injected with each dose of peptide evaluated.
Determination of indices of inflammation.
The numbers of
leukocytes present in the CSF were determined by appropriately diluting
CSF samples and counting the leukocytes using a Sysmex cell counter
(model CC-170M; TDA Corp., Kobe, Japan). The TNF content of serum and
CSF was determined by bioassay using WEHI 164 cells as indicator cells,
essentially as described previously (16). Human TNF-
(Boehringer Mannheim) was used as a standard. The limit of detection
was 0.05 ng/ml. CSF samples (10 µl) were assayed in triplicate, the
coefficient of variation being always less than 21% and usually less
than 11%. The CSF protein content was determined essentially according
to the method of Lowry et al. (30). Values presented are the
means ± the standard errors of the means (SEM). Statistical
analyses used rank sum tests (SigmaStat; Jandel Scientific).
Histological evaluation of brain. Rabbits were intracisternally administered 1,750 ng of hIL-8 and subsequently injected with either PFS or 25 ng of LPS at 8 h. At 12 h post-first injection, the rabbits were sacrificed and the brains were removed intact. No attempt was made to remove blood. Brains were fixed in 3.8% neutral phosphate-buffered formalin, trimmed, embedded in Paraplast (Zahner Electonic AG, Kaltbrunn, Switzerland), and sectioned nominally at 5 µm before staining with hematoxylin and eosin. Three sections, from different levels and encompassing meningeal and aqueductal surfaces, were examined histologically.
Intradermal IL-8 injection. The day before injection of IL-8, the backs of two rabbits were closely shaved and marked to locate injection sites. hIL-8 (17,500 ng/ml) was prepared in either PFS or freshly obtained rabbit CSF, and 0.1-ml volumes were injected intradermally in separate sites; PFS and CSF alone were also injected. The animals were sacrificed 2 h postinjection, and the skin surrounding the injection site was excised, stretched over cardboard, and fixed in 3.8% neutral phosphate-buffered formalin. Tissues were subsequently trimmed, embedded in Paraplast, sectioned at 4 µm, and stained with hematoxylin and eosin. Two sections per skin sample were examined histologically.
Anti-IL-8 antibody.
The monoclonal antibody (MAb) WS-4
(murine immunoglobulin G1
isotype), a well-characterized, specific
antibody, which neutralizes the activity of rabbit IL-8 in vivo
(20) and has been described previously (25), was
purified from mouse ascites using protein G-Sepharose (Pharmacia
Biotech, Uppsala, Sweden) according to the manufacturer's protocol.
Antibody was eluted with 0.1 M Tris-glycine (pH 3.0). The pH was
neutralized by the addition of 1 M Tris-HCl (pH 8.4), and the antibody
was dialyzed against PBS. WS-4 was prepared in pyrogen-free solutions
and tested negative for endotoxin in the Limulus assay.
Neutralization of in vivo IL-8 activity by anti-IL-8 antibody. For neutralization of IL-8 activity in CSF, WS-4 was diluted to 2.5 mg/ml in PFS containing 125 ng of E. coli LPS per ml, and 0.2 ml of this mixture was injected intracisternally into rabbits as described above. The predicted initial concentration of WS-4 was approximately 100 to 125 ng/ml of CSF, based upon the approximate volume of CSF in rabbits of this weight being 4 to 5 ml (36). WS-4 was also administered by an intravenous infusion of a 0.9-mg/ml antibody solution in PFS that was infused into rabbits over a 20-min period via the lateral ear vein; the predicted initial concentration of this antibody was 33 to 40 µg/ml of blood (based upon an approximately blood volume of 10% of the body weight). At the end of the infusion, 25 ng of E. coli LPS was injected intracisternally as described above. To control for the neutralizing activity of WS-4, recombinant IL-8 (rIL-8; 1,750 ng) with or without WS-4 (125 µg) in PFS was injected intradermally into rabbits as described above.
| |
RESULTS |
|---|
|
|
|---|
In vitro chemotaxis.
In vitro chemotaxis experiments using
leukocytes purified from rabbit peripheral blood demonstrated migratory
activity for both hIL-8 and rbIL-8 that was restricted to neutrophils
(Fig. 1). rbIL-8 was apparently slightly
more potent than hIL-8.
|
Intracisternal injection of IL-8 does not produce pleocytosis.
Various amounts of hIL-8 (1.75, 175, or 1,750 ng; to yield ca. 3.89 to
389 ng/ml of CSF) were injected in order to span the concentration
ranges determined in clinical specimens (ca. 0.02 to 150 ng/ml of CSF)
(7, 19, 26, 29, 39, 46, 49, 51, 57, 58, 62). Figure
2
demonstrates that, during an 8-h
period after the intracisternal injection of 1,750 ng of hIL-8, no
influx of leukocytes or accumulation of TNF or of total protein occurred in the CSF. Some rabbits were monitored for 12 h and did
not demonstrate any overt subarachnoid space inflammation (Fig. 2).
Similar results were obtained when smaller amounts of hIL-8 were
injected and when rabbits were given 7,200 ng of hIL-8 (Table
1). hNAP-2 and hGRO
(17.5, 175, or
1,750 ng), two homologous CXC chemokines with potent
neutrophil-activating properties (2, 63), also failed to
induce an inflammatory response (Table 1). In contrast, intracisternal
injection of 25 ng of LPS into rabbits (previously injected with hIL-8)
induced a vigorous inflammatory response characterized by a peak of TNF
activity (<0.14 ng of TNF/ml of CSF at 8 h; 80.2 ± 38.0 ng/ml of CSF at 10 h) and marked accumulation of leukocytes (<100
leukocytes/µl of CSF at 8 h; 5,250 ± 2,037 leukocytes/µl
of CSF at 12 h) and of protein (277 ± 40 µg/ml of CSF at
8 h; 1,290 ± 109 µg/ml of CSF at 12 h) within the CSF
(Fig. 2). TNF was never detected in serum (<0.5 ng/ml), and there was
approximately a 20% increase in circulating leukocytes. This slight
leukocytosis was also observed in rabbits that received saline
intracisternally (not shown). Rabbits receiving any of the chemokines
did not demonstrate an attenuated inflammatory response to LPS compared
to rabbits receiving PFS at 0 h and then LPS at 8 h (64 ± 12 ng of TNF/ml of CSF at 10 h; 7,000 ± 4,714 leukocytes/µl of CSF and 645 ± 64 µg of protein/ml of CSF at
12 h; n = 3; P > 0.05, rank sum test).
|
|
Histological evaluation of the effects of intracisternally
administered hIL-8.
The degree of leukocytosis in the CSF may not
correlate with the extent of inflammation occurring in the meninges
during meningitis (37). To address this point, histological
examination of the brains of rabbits that had received intracisternal
hIL-8 was performed to exclude the possibility that pleocytosis was
induced by hIL-8 but not associated with leukocytes appearing in the
CSF. Figure 3A demonstrates that at
12 h post-intracisternal injection of 1,750 ng of hIL-8, no
evidence of meningeal inflammation was apparent. Rabbits that had first
received hIL-8 and then 25 ng of LPS 8 h later showed a clear
accumulation of neutrophils in the meninges 4 h after the
injection of LPS (Fig. 3B). Similar results were obtained with rbIL-8
(not shown).
|
Histological evaluation of the effects of intradermal hIL-8.
To confirm that rabbits are indeed responsive to this IL-8 preparation,
1,750 ng of hIL-8 diluted in PFS or normal rabbit CSF was injected
intradermally into rabbits. Two hours later, the skin surrounding the
injection site was excised and processed for histological evaluation.
Figure 4 demonstrates that the hIL-8 used
in this study was active in vivo, producing a distinct accumulation of
neutrophils in the dermis (Fig. 4A). Similar results were obtained when
rbIL-8 was used (not shown). As a control, PFS alone was inactive (Fig.
4B). Since the degree of inflammatory response was similar between
hIL-8 diluted in PFS or CSF (Fig. 4C), the possibility that soluble
inhibitors of IL-8 mitigate its chemotactic activity in the CSF may be
excluded. Normal rabbit CSF (0.1 ml/site) was not found to be
proinflammatory (not shown).
|
Intracisternal administration of anti-IL-8 antibody reduces, but
fails to prevent, LPS-induced pleocytosis.
Despite being
apparently inactive as a single agent, IL-8 may act in concert with
other proinflammatory factors to induce neutrophil influx into the
subarachnoid space. To test this possibility, LPS (25 ng) was injected
either alone or together with the anti-IL-8 MAb WS-4 (500 µg) into
the CSF of rabbits, and the extent of pleocytosis was monitored (Fig.
5A). Although the presence of WS-4
decreased the maximum level of leukocytes about twofold (LPS alone,
8,693 ± 1,392 leukocytes/µl of CSF; LPS plus WS-4, 4,485 ± 881 leukocytes/µl of CSF; P < 0.02, rank sum
test), high intracisternal concentrations of inhibitory anti-IL-8
antibody had little effect on the overall pattern of LPS-induced
neutrophil influx. The effectiveness of WS-4 in neutralizing the
neutrophil chemotactic activity of rbIL-8 was confirmed by injecting
rbIL-8 (1,750 ng) with or without WS-4 (125 µg) into rabbit skin
(Fig. 6).
|
|
Intravenous administration of anti-IL-8 antibody strongly inhibits LPS-induced pleocytosis. Experimental data suggest that adhesion of circulating blood leukocytes to endothelium and subsequent extravagation (transmigration) are induced by chemokines immobilized or exposed on the endothelial cell surface (43, 53, 61). To test whether neutralizing antibody to IL-8 administered on the bloodstream side of the blood-brain barrier is capable of blocking LPS-dependent pleocytosis, WS-4 antibody (10 mg/rabbit) was injected intravenously before intracisternal administration of 25 ng of LPS; this WS-4 antibody dose was previously shown to block LPS-induced neutrophil influx into rabbit skin (20). The results presented in Fig. 5B indicate that pleocytosis was effectively inhibited by intravenous anti-IL-8 MAb (control, 7,030 ± 2,053 leukocytes/µl of CSF at 4 h; WS-4-treated, 544 ± 216 leukocytes/µl of CSF at 6 h; between 4 and 8 h, all the differences were statistically significant [P < 0.01, rank sum test]). Intravenous WS-4 had little effect on the pattern of TNF production within the CSF: peak concentrations may have been slightly reduced (control, 47 ± 12 ng of TNF/ml of CSF; WS-4 treated, 37 ± 10 ng/ml of TNF; P > 0.05, rank sum test), but the overall kinetics of production were unaffected by the antibody (not shown).
| |
DISCUSSION |
|---|
|
|
|---|
Given that IL-8 can induce transmigration of neutrophils across endothelia in vitro (27, 47) and in vivo (11) and that elevated CSF IL-8 concentrations occur in meningitis patients (7, 19, 26, 29, 39, 46, 49, 51, 57, 58, 62), IL-8 could perhaps be involved in the inflammatory signals that result in pleocytosis during bacterial meningitis.
However, the results obtained by the present study, in which IL-8 was administered intracisternally to rabbits, suggest that elevated CSF IL-8 levels per se are not sufficient to induce influx of neutrophils into the subarachnoid space or to damage the blood-brain barrier, as evidenced by the absence of protein leakage into the CSF. In contrast, hIL-8 and rbIL-8 preparations induced inflammatory reactions in rabbit skin, proving the activity of the peptide preparations used in the present study. Results obtained with purified rbIL-8 suggest that the observed inactivity of hIL-8 is not due to an unexpected species difference in relative potency within this anatomical site. Apparently transcytosis of CSF IL-8 does not occur or is insufficient to fully activate the specialized endothelium of the blood-brain barrier, in contrast to that occurring with other endothelia (33). Injection of PGE2 into the CSF has been previously shown to heighten the permeability of the blood-brain barrier, as indicated by increases in CSF protein levels (24), and to also potentiate the chemotactic activity of IL-8 (9, 18). However, either pretreatment or coinjection with PGE2 failed to reverse the apparent inactivity of hIL-8 present within the subarachnoid space. hIL-8 diluted in PFS or rabbit CSF resulted in a similar degree of dermal neutrophil accumulation, suggesting that there is no soluble inhibitor of IL-8 within normal CSF. Degradation of this chemokine by proteases resulting in loss of activity is unlikely, given the extreme stability of IL-8 (40).
Our results do not exclude the presence of a potent cell-associated
chemokine inhibitor in neural tissue that prevents IL-8 (or GRO
- or
NAP-2-)-mediated responses. Since intracisternal injection of the
low-molecular-weight chemotactic peptides fMLP (54) and C5a
(24) and the chemokines MIP-2 and MIP-1 (44) was
shown to induce neutrophilic pleocytosis, quiescent tissues within the
subarachnoid space may possess an inhibitory capacity that is specific
for certain chemokines. Inhibition of the activity of IL-8 can occur by
a cell-bound "scavenger" chemokine receptor similar to that present
on erythrocytes (14, 21); in support of this, the Duffy
antigen receptor for chemokines (DARC) has been shown to be expressed
in brain tissue (22). Once an inflammatory process has been
initiated within the subarachnoid space, one might speculate that IL-8
is coinduced with a factor(s) (e.g., a protease) to overcome this
inhibitor. However, evidence for this hypothesis requires further experimentation.
The apparent lack of IL-8 proinflammatory activity in the CSF would
seem to contradict the experimental demonstration (1, 4) of
a neutrophil recruitment at areas distal to the injection site
following intrahippocampal injection of high amounts of IL-8 (to
achieve ca. 104 to 106 ng/ml). Neutrophil
accumulation in brain tissue was slow (ca. 24 h postinjection
[1]), suggesting that there are important differences
in the response to IL-8 depending upon the exact anatomical site in the
brain where IL-8 is injected (reviewed in references 31 and 41). Although elevated CSF
levels of IL-8 alone are apparently unable to invoke meningeal
inflammation, this chemokine may still act in concert with other
cytokines to mediate inflammation within the subarachnoid space (e.g.,
TNF potentiates the activity of IL-8 and NAP-2 [5, 25,
52]). However, the poor inhibition of LPS-induced pleocytosis
by intracisternal anti-rabbit IL-8 MAb WS-4 would argue against a
strong involvement of locally produced CSF IL-8 in the transmigration
of neutrophils across the blood-brain barrier endothelium, even if
acting in concert with other proinflammatory cytokines. The presence of
anti-IL-8 MAb in the CSF only partially reduced the maximal leukocyte
levels and little altered the kinetics of leukocyte influx. Although
WS-4 is a well-characterized and specific MAb, a nonspecific effect of
the antibody cannot be strictly ruled out; this suggests either that
CSF IL-8 plays only a minor role or that other proinflammatory
mediators, potentially including other antigenically dissimilar
chemokines likely to be present in the CSF during meningitis, may
render the effects of IL-8 relatively redundant. In congruence with
this, although MIP-1
and MIP-2 have been implicated in experimental
L. monocytogenes meningitis (45) and MIP-2 and
MIP-1 administered intracisternally to rabbits induced neutrophil
influx into the subarachnoid space (44), antibody
neutralization of these chemokines only slightly delayed onset of
inflammation during pneumococcal infection (44).
Intracisternal administration of anti-rabbit IL-8 antibody did not
affect the inflammatory response to pneumococcal meningitis in rabbits
(Østergaard et al., Abstr. 39th Intersci. Conf. Antimicrob. Agents
Chemother.). Furthermore, antibody neutralization of IL-8 only
partially reduced neutrophil chemotactic activity of CSF ex vivo
(49).
In contrast to the weak activity of WS-4 in the CSF, this anti-rabbit IL-8 MAb in the bloodstream was particularly effective in blocking LPS-induced neutrophil migration into the CSF, strongly implicating IL-8 as a dominant mediator in this inflammatory process. Although a nonspecific effect of this low concentration of antibody cannot be ruled out, this would suggest that the anti-IL-8 MAb in the bloodstream is neutralizing IL-8 sequestered from this receptor, possibly in the vicinity of, or associated with the surface of, activated endothelial cells of the blood-brain barrier. However, other inflammatory mediators induced by LPS may enhance the permeability of this lining barrier, allowing a chemotactic gradient of IL-8 to be established from the CSF (high IL-8 concentration) to neutrophils within meningeal or choroidal venules.
There is compelling evidence that IL-8 can be bound to the endothelial surface (42) and therefore is acting in a haptotactic manner rather than presenting a soluble molecule gradient (42, 43). In this case, the endothelium of the blood-brain barrier (or cells within the subarachnoid space), stimulated by bacterial invasion, invokes an inflammatory response producing IL-8 that crosses the endothelium by transcytosis to specific areas on the endothelium microvilli (33), binds to cell surface glycosaminoglycans (e.g., heparin sulfate [33, 53, 61] and DARC [21]), and anchors to the endothelium via the C terminus to expose the receptor-interactive N-terminal domain (21). Such surface-bound IL-8 presents a chemotactic stimulus to leukocytes but should also be accessible to anti-IL-8 antibody in the circulation. However, not all endothelial cells show the same IL-8 binding responses (33), and this needs to be determined for the specialized endothelia of the blood-brain barrier. These data would also suggest that caution should be applied in studies assessing the potential role of proinflammatory factors in meningitis when intracisternal injection is the only method of evaluation.
Chemokines have been recognized as a suitable target for therapeutic intervention against inflammatory diseases (48). Despite the presence of a large variety of chemotactic peptides in the CSF from meningitis patients (28), the present data indicate a central role for IL-8 in subarachnoid space inflammation during meningitis; a precise mechanistic depiction awaits further elucidation. Nonetheless, the data suggest IL-8 to be a well-defined target for the adjunct treatment of meningitis.
| |
ACKNOWLEDGMENTS |
|---|
We thank J. Vaxelaire, S. Kunz, and M. Hattenberger for technical
assistance; Antal Rot for his review of the manuscript; Alfred Walz for
his help in the purification of rIL-8; and Ian Clark-Lewis for
providing synthetic hIL-8, hNAP-2, and hGRO
.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Novartis Pharma AG, WKL 125.1.05, CH-4002 Basel, Switzerland. Phone: 41-61-696-3427. Fax: 41-61-696-6242. E-mail: terence.oreilly{at}pharma.novartis.com.
Present address: Oregon Hearing Research Center, Oregon Health
Sciences University, Portland, OR 97207.
Present address: DuPont Merck R&D, Stine-Haskell Research Center,
Newark, DE 19174-0030.
Editor: E. I. Tuomanen
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Andersson, P.-B.,
V. H. Perry, and S. Gordon.
1992.
Intracerebral injection of proinflammatory cytokines or leukocyte chemotaxins induces minimal myelomonocytic cell recruitment to the parenchyma of the central nervous system.
J. Exp. Med.
176:255-259 |
| 2. | Baggiolini, M., B. Dewald, and B. Moser. 1997. Human chemokines: an update. Annu. Rev. Immunol. 15:675-705[CrossRef][Medline]. |
| 3. | Beaubien, B. C., P. D. Collins, P. J. Jose, N. F. Totty, J. Hsuan, M. D. Waterfield, and T. J. Williams. 1990. A novel neutrophil chemoattractant generated during an inflammatory reaction in the rabbit peritoneal cavity in vivo. Biochem. J. 271:797-801[Medline]. |
| 4. | Bell, M. D., D. D. Taub, and V. H. Perry. 1996. Overriding the brain's intrinsic resistance to leukocyte recruitment with intraparenchymal injections of recombinant chemokines. Neuroscience 74:283-292[CrossRef][Medline]. |
| 5. |
Brandt, E.,
F. Petersen, and H. P. Flad.
1992.
Recombinant tumor necrosis factor- potentiates neutrophil degranulation in response to host defence cytokines neutrophil-activating peptide 2 and IL-8 by modulating intracellular cyclic AMP levels.
J. Immunol.
149:1356-1364[Abstract].
|
| 6. | Braun, J. S., and E. I. Tuomanen. 1999. Molecular mechanisms of brain damage in bacterial meningitis. Adv. Pediatr. Infect. Dis. 14:49-71[Medline]. |
| 7. | Chaka, W., R. Heyderman, I. Gangaidzo, V. Robertson, P. Mason, J. Verhoef, A. Verheul, and A. I. Hoepelman. 1997. Cytokine profiles in cerebrospinal fluid of human immunodeficiency virus-infected patients with cryptococcal meningitis: no leukocytosis despite high interleukin-8 levels. J. Infect. Dis. 176:1633-1636[Medline]. |
| 8. | Clark-Lewis, I., B. Moser, A. Walz, M. Baggiolini, G. J. Scott, and R. Aebersold. 1991. Chemical synthesis, purification, and characterisation of two inflammatory proteins, neutrophil activating peptide 1 (interleukin-8) and neutrophil activating peptide 2. Biochemistry 30:3128-3135[CrossRef][Medline]. |
| 9. | Colditz, I. G. 1990. Effect of exogenous prostaglandin E2 and actinomycin D on plasma leakage induced by neutrophil-activating peptide-1/interleukin-8. Immunol. Cell. Biol. 68:397-403. |
| 10. | Colditz, I. G., R. D. Zwahlen, and M. Baggiolini. 1990. Neutrophil accumulation and plasma leakage induced in vivo by neutrophil-activating peptide-1. J. Leukoc. Biol. 48:129-137[Abstract]. |
| 11. | Colditz, I. G., R. D. Zwahlen, B. Dewald, and M. Baggiolini. 1989. In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes. Am. J. Pathol. 134:755-760[Abstract]. |
| 12. | Collins, P. D., P. J. Jose, and T. J. Williams. 1991. The sequential generation of neutrophil chemoattractant proteins in acute inflammation in the rabbit in vivo. J. Immunol. 146:677-684[Abstract]. |
| 13. |
Dacey, R. G., and M. A. Sande.
1974.
Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.
Antimicrob. Agents Chemother.
6:437-441 |
| 14. | Darbonne, W. C., G. C. Rice, M. A. Mohler, T. Apple, C. A. Hébert, A. J. Valente, and J. B. Baker. 1991. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J. Clin. Investig. 88:1362-1369. |
| 15. |
Diab, A.,
H. Abdalla,
H. N. Li,
F. D. Shi,
J. Zhu,
B. Höjberg,
L. Lindquist,
B. Wretlind,
M. Bakhiet, and H. Link.
1999.
Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1 attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis.
Infect. Immun.
67:2590-2601 |
| 16. | Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods 95:99-105[CrossRef][Medline]. |
| 17. | Feldman, W. E. 1977. Relation of concentrations of bacteria and bacterial antigen in cerebrospinal fluid to prognosis in patients with bacterial meningitis. N. Engl. J. Med. 296:433-435[Medline]. |
| 18. | Foster, S. J., D. M. Aked, J.-M. Schröder, and E. Christophers. 1989. Acute inflammatory effects of a monocyte-derived neutrophil-activating peptide in rabbit skin. Immunology 67:181-183[Medline]. |
| 19. | Halstensen, A., M. Ceska, P. Brantzaeg, H. Redl, A. Naess, and A. Waage. 1993. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease. J. Infect. Dis. 167:471-475[Medline]. |
| 20. | Harada, A., N. Sekido, K. Kuno, M. Akiyama, T. Kasahara, I. Nakanishi, N. Mukaida, and K. Matsushima. 1993. Expression of recombinant rabbit IL-8 in Escherichia coli and establishment of the essential involvement of IL-8 in recruiting neutrophils into lipopolysaccharide-induced inflammatory site of rabbit skin. Int. Immunol. 6:681-690. |
| 21. | Horuk, R., T. J. Colby, W. C. Darbonne, T. J. Schall, and K. Neote. 1993. The human erythrocyte inflammatory peptide (chemokine) receptor. Biochemical characterisation, solubilization, and development of a binding assay for the soluble receptor. Biochemistry 32:5733-5738[CrossRef][Medline]. |
| 22. | Horuk, R., A. Martin, J. Hesselgesser, T. Hadley, Z. Lu, Z. Wang, and S. C. Peiper. 1996. The Duffy antigen receptor for chemokines: structural analysis and expression in the brain. J. Leukoc. Biol. 59:29-38[Abstract]. |
| 23. |
Huber, A. R.,
S. L. Kunkel,
R. F. Todd, and S. J. Weiss.
1991.
Regulation of transendothelial neutrophil migration by endogenous interleukin-8.
Science
254:99-102 |
| 24. | Kadurugamuwa, J. L., B. Hengstler, M. A. Bray, and O. Zak. 1989. Inhibition of complement-factor-5a-induced inflammatory reactions by prostaglandin E2 in experimental meningitis. J. Infect. Dis. 160:715-719[Medline]. |
| 25. | Ko, Y.-C., N. Mukaida, A. Panyutich, N. N. Voitenok, K. Matsushima, T. Kawai, and T. Kasahara. 1992. A sensitive enzyme-linked immunosorbent assay for human interleukin-8. J. Immunol. Methods 149:227-235[CrossRef][Medline]. |
| 26. | Kornelisse, R. F., H. F. J. Sacelkoul, P. H. G. Mulder, M. H. Suur, P. J. C. van der Straaten, A. J. van der Heijden, R. N. Sukhai, K. Hählen, H. J. Neijens, and R. de Groot. 1996. Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis. J. Infect. Dis. 173:1498-1502[Medline]. |
| 27. | Kossmann, T., P. F. Stahel, P. M. Lenzlinger, H. Redl, R. W. Dubs, O. Trentz, G. Schlag, and M. C. Morganti-Kossmann. 1997. Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production. J. Cereb. Blood Flow Metab. 17:280-289[CrossRef][Medline]. |
| 28. | Lahrtz, F., L. Piali, K. S. Spanaus, J. Seebach, and A. Fontana. 1998. Chemokines and chemotaxis of leukocytes in infectious meningitis. J. Neuroimmunol. 85:33-43[CrossRef][Medline]. |
| 29. | López-Cortés, L. F., M. Cruz-Ruiz, J. Gómez-Mateos, P. Viciana-Fernandez, F. J. Martinez-Marcos, and J. Pachón. 1995. Interleukin-8 in cerebrospinal fluid from patients with meningitis of different etiologies: Its possible role as a neutrophil chemotactic factor. J. Infect. Dis. 172:581-584[Medline]. |
| 30. |
Lowry, O. H.,
N. J. Rosebrough,
A. L. Farr, and R. J. Randall.
1951.
Protein measurement with the folin phenol reagent.
J. Biol. Chem.
193:265-275 |
| 31. | Martiney, J. A., C. Cuff, M. Litwalk, J. Berman, and C. F. Bronsan. 1998. Cytokine-induced inflammation in the central nervous system revisited. Neurochem. Res. 23:349-359[CrossRef][Medline]. |
| 32. | Mastroianni, C. M., L. Lancella, F. Mengoni, M. Lichtner, P. Santopadre, C. D'Agostino, F. Ticca, and V. Vullo. 1998. Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and tuberculous meningitis. Clin. Exp. Immunol. 114:210-214[CrossRef][Medline]. |
| 33. | Middleton, J., S. Neil, J. Wintle, I. Clark-Lewis, H. Moore, C. Lam, M. Auer, E. Hub, and A. Rot. 1997. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91:385-395[CrossRef][Medline]. |
| 34. | Morganti-Kossman, M. C., P. M. Lenzlinger, V. Hans, P. Stahel, E. Csuka, E. Ammann, R. Stocker, O. Trentz, and T. Kossmann. 1997. Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol. Psychiatry 2:133-136[CrossRef][Medline]. |
| 35. | Mukaida, N., A. Harada, and K. Matsushima. 1998. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev. 9:9-23[CrossRef][Medline]. |
| 36. | Mustafa, M. M., O. Ramilo, K. D. Olsen, P. S. Franklin, E. J. Hansen, B. Beutler, and G. H. McCracken. 1989. Tumor necrosis factor in mediating experimental Haemophilus influenzae type b meningitis. J. Clin. Investig. 84:1253-1259. |
| 37. | Nolan, C. M., C. K. McAllister, E. Walters, and H. N. Beaty. 1987. Experimental pneumococcal meningitis IV. The effect of methyl prednisolone on meningeal inflammation. J. Lab. Clin. Med. 91:979-988. |
| 38. |
Østergaard, C.,
T. L. Benfield,
B. Gesser,
A. Kharazmi,
N. Frimodt-Møller,
F. Espersen, and J. D. Lundgren.
1999.
Pretreatment with granulocyte colony-stimulating factor attenuates the inflammatory response but not the bacterial load in cerebrospinal fluid during experimental pneumococal meningitis in rabbits.
Infect. Immun.
67:3430-3436 |
| 39. | Østergaard, C., T. L. Benfield, F. Sellebjerg, G. Kronborg, N. Lohse, and J. D. Lundgren. 1996. Interleukin-8 in cerebrospinal fluid from patients with septic and aseptic meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 15:166-169[CrossRef][Medline]. |
| 40. |
Peveri, P.,
A. Walz,
B. Dewald, and M. Baggiolini.
1988.
A novel neutrophil-activating factor produced by human mononuclear phagocytes.
J. Exp. Med.
167:1547-1559 |
| 41. | Ransohoff, R. M., and M. Tani. 1998. Do chemokines mediate leukocyte recruitment in post-traumatic CNS inflammation? Trends Neurosci. 21:154-159[CrossRef][Medline]. |
| 42. | Rot, A. 1993. Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur. J. Immunol. 23:303-306[Medline]. |
| 43. | Rot, A., E. Hub, J. Middleton, F. Pons, C. Rabeck, K. Thierer, J. Wintle, B. Wolff, M. Zsak, and P. Dukor. 1996. Some aspects of IL-8 pathophysiology III: chemokine interaction with endothelial cells. J. Leukoc. Biol. 59:39-44[Abstract]. |
| 44. |
Saukkonen, K.,
S. Sande,
C. Cioffe,
S. Wolpe,
B. Sherry,
A. Cerami, and E. Tuomanen.
1990.
The role cytokines in the generation of inflammation and tissue damage in experimental gram-positive meningitis.
J. Exp. Med.
171:439-448 |
| 45. |
Seebach, J.,
D. Bartholdi,
K. Frei,
K.-S. Spanaus,
E. Ferrero,
U. Widmer,
S. Isenmann,
R. M. Strieter,
M. Schwab,
H.-W. Pfister, and A. Fontana.
1995.
Experimental Listeria meningoencephalitis. Macrophage inflammatory protein-1 and -2 are produced intrathecally and mediate chemotactic activity in cerebrospinal fluid of infected mice.
J. Immunol.
155:4367-4375[Abstract].
|
| 46. | Seki, T., K. Joh, and T. Oh-Ishi. 1993. Augmented production of interleukin-8 in cerebrospinal fluid in bacterial meningitis. Immunology 80:333-335[Medline]. |
| 47. | Smith, W. B., J. R. Gamble, I. Clark-Lewis, and M. A. Vadas. 1991. Interleukin-8 induces neutrophil transendothelial migration. Immunology 72:65-72[Medline]. |
| 48. | Sozzani, S., P. Allavena, P. Proost, J. van Damme, and A. Mantovani. 1996. Chemokines as targets for pharmacological intervention. Prog. Drug Res. 47:53-80[Medline]. |
| 49. | Spanaus, K.-S., D. Nadal, H.-W. Pfister, J. Seebach, U. Widmer, K. Frei, S. Gloor, and A. Fontana. 1997. C-X-C and C-C chemokines are expressed in the cerebrospinal fluid in bacterial meningitis and mediate chemotactic activity on peripheral blood-derived polymorphonuclear and mononuclear cells in vitro. J. Immunol. 158:1956-1964[Abstract]. |
| 50. | Spector, R., and A. V. Lorenzo. 1974. Inhibition of penicillin transport from the cerebrospinal fluid after intracisternal inoculation of bacteria. J. Clin. Investig. 54:316-325. |
| 51. | Sprenger, H., A. Rösler, P. Tonn, H. J. Braune, G. Huffmann, and D. Gemsa. 1996. Chemokines in the cerebrospinal fluid of patients with meningitis. Clin. Immunol. Immunopathol. 80:155-161[CrossRef][Medline]. |
| 52. |
Strieter, R. M.,
S. L. Kunkel,
H. J. Showell,
D. G. Remick,
S. H. Phan,
P. A. Ward, and R. M. Marks.
1989.
Endothelial cell gene expression of a neutrophil chemotactic factor by TNF- , LPS and IL-1 .
Science
243:1467-1469 |
| 53. | Tanaka, Y., D. H. Adams, and S. Shaw. 1993. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol. Today 14:111-115[CrossRef][Medline]. |
| 54. | Täuber, M. G., U. Borschberg, and M. A. Sande. 1988. Influence of granulocytes on brain edema, intracranial pressure, and cerebrospinal fluid concentrations of lactate and protein in experimental meningitis. J. Infect. Dis. 157:456-464[Medline]. |
| 55. | Täuber, M. G., and B. Moser. 1999. Cytokines and chemokines in meningeal inflammation: biology and clinical implications. Clin. Infect. Dis. 28:1-12[Medline]. |
| 56. | Thomas, K. M., L. Taylor, G. Prado, J. Romero, B. Moser, B. Car, A. Walz, M. Baggiolini, and J. Navarro. 1994. Functional and ligand binding specificity of the rabbit neutrophil IL-8 receptor. J. Immunol. 152:2496-2500[Abstract]. |
| 57. | van Deuren, M., J. van der Ven-Jongekrig, A. K. M. Bartelink, R. van Dalen, R. W. Sauerwein, and J. W. M. van der Meer. 1995. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J. Infect. Dis. 172:433-439[Medline]. |
| 58. |
van Meir, E.,
M. Ceska,
F. Effenberger,
A. Walz,
E. Grouzmann,
I. Desbaillets,
K. Frei,
A. Fontana, and N. de Tribolet.
1992.
Interleukin-8 is produced in neoplastic and infectious diseases of the human nervous system.
Cancer Res.
52:4297-4305 |
| 59. | Walz, A., P. Peveri, H. Aschauer, and M. Baggiolini. 1987. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem. Biophys. Res. Commun. 149:755-761[CrossRef][Medline]. |
| 60. |
Walz, A.,
R. Burgener,
B. D. Car,
M. Baggiolini,
S. L. Kunkel, and R. M. Strieter.
1991.
Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to IL-8.
J. Exp. Med.
174:1355-1362 |
| 61. | Witt, D. P., and A. D. Lander. 1994. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr. Biol. 4:394-400[CrossRef][Medline]. |
| 62. | Yokoyama, T., M. Oda, S. Ogura, T. Horiuchi, and Y. Seno. 1996. Relationship of interleukin-8 and colony-stimulating factors to neutrophil migration in aseptic meningitis. Acta Paediatr. 85:303-307[Medline]. |
| 63. | Zlotnik, A., J. Morales, and J. A. Hedrick. 1999. Recent advances in chemokines and chemokine receptors. Crit. Rev. Immunol. 19:1-47[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. |
|---|